(S)-10-Hydroxycamptothecin-d5(Synonyms: 10-HCPT-d5; 10-Hydroxycamptothecin-d5)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

(S)-10-Hydroxycamptothecin-d5 (Synonyms: 10-HCPT-d5; 10-Hydroxycamptothecin-d5)

(S)-10-Hydroxycamptothecin-d5 (10-HCPT-d5) 是氘代的 (S)-10-Hydroxycamptothecin。(S)-10-Hydroxycamptothecin (10-HCPT) 是一种从喜树中分离的 DNA 拓扑异构酶 I (DNA topoisomerase I) 抑制剂。(S)-10-Hydroxycamptothecin 可显着诱导细胞凋亡,并可用于肝癌,胃癌,结肠癌和白血病的研究。

(S)-10-Hydroxycamptothecin-d5(Synonyms: 10-HCPT-d5;  10-Hydroxycamptothecin-d5)

(S)-10-Hydroxycamptothecin-d5 Chemical Structure

CAS No. : 1330277-66-1

规格 是否有货
1 mg Check price and availability
10 mg Check price and availability

* Please select Quantity before adding items.

生物活性

(S)-10-Hydroxycamptothecin-d5 (10-HCPT-d5) is the deuterium labeled (S)-10-Hydroxycamptothecin. (S)-10-Hydroxycamptothecin (10-HCPT) is a DNA topoisomerase I inhibitor. (S)-10-Hydroxycamptothecin exhibits a remarkable apoptosis-inducing effect. (S)-10-Hydroxycamptothecin has the potential for hepatoma, gastric carcinoma, colon cancer and leukaemia research[1][2][3][4].

体外研究
(In Vitro)

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

369.38

Formula

C20H11D5N2O5

CAS 号

1330277-66-1

中文名称

(S)-10-羟基喜树碱 d5

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

    [2]. Min Liu, et al. Intracellular delivery of 10-hydroxycamptothecin with targeted nanostructured lipid carriers against multidrug resistance . Journal of Drug Targeting.

    [3]. Min Liu, et al. Intracellular delivery of 10-hydroxycamptothecin with targeted nanostructured lipid carriers against multidrug resistance. J Drug Target, Early Online: 1–8

    [4]. Yu P, et al. Synthesis and preliminary anticancer evaluation of 10-hydroxycamptothecin analogs. Biol Pharm Bull. 2012;35(8):1295-9.

    [5]. Zhang XW, et al. Differentiation-inducing action of 10-hydroxycamptothecin on human hepatoma Hep G2 cells. Acta Pharmacol Sin. 2000 Apr;21(4):364-8.

    [6]. Zhang XW, et al. Differential regulation of P53, c-Myc, Bcl-2, Bax and AFP protein expression, and caspase activity during 10-hydroxycamptothecin-induced apoptosis in Hep G2 cells. Anticancer Drugs. 2000 Oct;11(9):747-56.

    [7]. Liu M, et al. Intracellular delivery of 10-hydroxycamptothecin with targeted nanostructured lipid carriers against multidrug resistance. J Drug Target. 2016;24(5):433-40.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务